12 January 2026
12 January 2026
Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.
Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.
GlobalData’s detailed strategic reports on the MFN executive order and on the GENEROUS model examined how some of the known adverse effects of IRP will be unleashed.
Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m.
The new purpose-built facility is scheduled to become operational by 2029.
The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.
Alveus will use the funds to support a Phase II trial and progress more assets towards the clinic.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
